I-MAB Filed 2023 Annual Report on Form 20-F
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.
馬里蘭州羅克維爾，2024年4月30日 /PRNewswire/ — 總部位於美國的全球生物技術公司I-Mab（“公司”）（納斯達克股票代碼：IMAB）專門專注於治療癌症的高度差異化免疫療法的開發和潛在商業化，今天宣佈已向美國證券交易委員會提交了截至2023年12月31日止年度的20-F表年度報告（“SEC”）於 2024 年 4 月 30 日發佈。
The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400, Rockville, MD, 20850.
該年度報告可在公司的投資者關係網站上查閱，網址爲 ir.i-mabbiopharma.com 並在美國證券交易委員會的網站上 www.sec.gov。公司將應書面要求向其股東和ADS持有人免費提供年度報告的紙質副本。申請應發送至投資者關係部，I-Mab，2440 Research Blvd.，400套房，馬里蘭州羅克維爾，20850。
About I-Mab
關於 i-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab（納斯達克股票代碼：IMAB）是一家總部位於美國的全球生物技術公司，專門致力於治療癌症的高差異化免疫療法的開發和潛在商業化。I-Mab 已在美國馬里蘭州羅克維爾和加利福尼亞州聖地亞哥開展業務。欲了解更多信息，請訪問 http://www.i-mabbiopharma.com 然後關注我們 領英 和 X。
I-Mab Contacts
i-Mab 聯繫人
| Investors & Media |
| Tyler Ehler |
| Senior Director, Investor Relations |
| 投資者與媒體 |
| 泰勒·埃勒 |
| 投資者關係高級董事 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html
SOURCE I-Mab Biopharma
來源 I-Mab Biopharma
譯文內容由第三人軟體翻譯。